Gabapentin

Epilepsia

Volumn 40, Issue SUPPL. 5, 1999, Pages s63-s70

  Morris, George L ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE   (United States)

Author keywords

Adverse experience; Anticonvulsants; Clinical trials; Clinical use; GBP; Neuropharmacology; Open label trials; Post marketing data

Indexed keywords

GABAPENTIN;

AGITATION; ANTICONVULSANT ACTIVITY; ATAXIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESEARCH; EPILEPSY; HUMAN; HYPERACTIVITY; IRRITABILITY; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO;

EID: 0032861737     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00921.x     Document Type: Review

References (38)

1. Taylor CP, Gee NS, Su TZ. et al. A summary of mechanistic hypothesis of gabapentin pharmacology. Epilepsy Res 1998,29: 233-49.
2. Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998;37:83-91.
3. Bartoszyk GD, Fritschie, Herrmann M, et al. Indications for an involvement of the GABA-system in the mechanism of action of gabapentin [Abstract]. Arch Pharmacol 1983;322(suppl):R94.
4. McDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1993;34(suppl 5):S1-8.
5. Taylor CP. Mechanisms of action of gabapentin. Drugs Today 1998;34(suppl D):3-11.
6. Crawford P, Ghadiali E, Lang R, et al. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987;50:682-6.
7. Bower G, Bochinger D, Castell M, et al. Gabapentin in the treatment of drug resistant epileptic patients. Adv Epileptol 1989;7: 219-21.
8. Sivenius J, Kalviainen R, Ylinen A, et al. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991;32: 539-42.
9. UK Gabapentin Study Group. Gabapentin and partial epilepsy. Lancet 1990;335:1114-7.
10. US Gabapentin Study Group No. 5. Gabapentin as add on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-8.
11. Anhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (Neurontin) as add on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994;35:795-801.
12. Beydoun A, Fischer J, Labard R, et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from poly-therapy in outpatients with refractory complex partial or secondary generalized seizures. Neurology 1997;49: 746-52.
13. Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy: I. An eight day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology 1997;49:739-45.
14. Leber PD. Hazards of inference: the active control investigation. Epilepsia 1989;30(suppl 1):S57-63.
15. Trudeau V, Myers S, LaMoreaux L, Anhut H, Garfalo E, Ebersole J. Gabapentin in naïve childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996;11:470-5.
16. Chadwick DW, Liederman DB, Sauermann W, Alexander J, Garfalo E. Gabapentin in generalized seizures. Epilepsy Res 1996; 25:191-7.
17. Appleton R, Fichtner K, Murray G, et al. Gabapentin in children with refractory partial seizures: a 12-week, double-blind, placebo-controlled study [Abstract]. Proc Am Epilepsy Soc Meet 1998; .
18. Bourgeois B, Brown LW, Pellock JM, et al. Gabapentin monotherapy in children with benign childhood epilepsy with centro-temporal spikes (BECTS): a 36-week, double-blind, placebo-controlled study [Abstract]. Am Proc Epilepsy Soc Meet 1998; .
19. Chadwick DW, Anhul H, Griener MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group. Neurology 1998;51:1282-8.
20. Morreli M, et al. Efficacy of gabapentin as adjunctive therapy in a large multicenter study. [submitted].
21. Bruni J. Outcome observation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. NEON evaluation of outcomes in neurological practice. Can J Neurol Sci 1998;25:134-40.
22. Beydoun A, Fakhouri T, Nasreddine W, Abou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory epilepsy. Epilepsia 1998;39:188-93.
23. Wilson AE, Sills GJ, Forrest G, Brodie MJ. High dose gabapentin in refractory partial seizures: clinical observations in 50 patients. Epilepsy Res 1998;29:161-6.
24. Khaurana DS, Riviello J, Helmers S, Holmes G, Anderson J, Mikati MA. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996;128:829-33.
25. Lee DO, Steingard RJ, Cesna M, et al. Behavioral side effects of gabapentin in children. Epilepsia 1996;37:87-90.
26. Tallian KB, Nahata MC, Low W, et al. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996;37:501-2.
27. Wolf SM, Shinnar S, Kang H, et al. Gabapentin toxicity in children manifesting as behavior changes. Epilepsia 1996;36:1203-5.
28. Morris GL. Efficacy and tolerability of gabapentin in clinical practice. Clin Ther 1995;17:891-900.
29. Harden CL, Hosain S, Nikolov B, Labar DR. Evaluation of gabapentin in an outpatient and office-based sample of epilepsy patients. J Epilepsy 1998;11:130-5.
30. Baulac M, Cavalcanti D, Semah F, Arzimanoglou A, Poltal JJ. Gabapentin add-on therapy with adaptable doses in 610 patients with partial epilepsy: an open observational study. The French Gabapentin Collaborative Group. Seizure 1998;7:55-62.
31. Browne TR. Efficacy and Safety of Gabapentin. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services, 1993:47-57.
32. US Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug resistant partial epilepsy. Epilepsy Res 1994;18:67-73.
33. Walker MC, Patsalos PN. The tolerability and safety profile of gabapentin. Rev Contemp Pharmacother 1996;7:249-57.
34. Parke-Davis. Data on file. Morris Plains, NJ, 1993.
35. Ramsey RE. Clinical efficacy and safety of gabapentin. Neurology 1994;44(suppl 5):S23-30.
36. Neurontin®. Gabapentin capsules package insert. Morris Plains, NJ, 1993.
37. Fischer RS, Penovich P, Pellock J, Sachdeo R. A multicenter, randomized, double-blind comparative study of gabapentin administered as an initial dosage of 900 mg/day versus a dosage titrated to 900 mg/d over 3 days. Neurology 1996;46(suppl):A169.
38. Gidal BE, Maly MM, Budde J, Lensmeyer GL, Pitterle ME, Jones JC. Effect of a high-protein meal on gabapentin pharmacokinetics. Epilepsy Res 1996;23:71-6.